NYSE:BMYBristol-Myers Squibb Stock Price, Forecast & News

$55.53

+0.32 (+0.58 %)

(As of 04/3/2020 04:00 PM ET)

Add

Compare

Today's Range

$54.90

Now: $55.53▼

$56.47

50-Day Range

$46.40

MA: $58.04▼

$67.00

52-Week Range

$42.48

Now: $55.53▼

$68.34

Volume14.65 million shs

Average Volume20.09 million shs

Market Capitalization$125.36 billion

P/E Ratio25.36

Dividend Yield3.26%

Beta0.74

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, the company offers Reyataz, a protease inhibitor for the treatment of human immunodeficiency virus (HIV) and Evotaz; Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. It has collaboration agreements with Nektar Therapeutics; Janssen Pharmaceuticals, Inc.; Biocartis Group NV.; and FameWave Ltd. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Beat the Market (BTM) Rank^™

3.4 Analyst's Opinion

Consensus Rating
Bristol-Myers Squibb has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 12 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $64.33, Bristol-Myers Squibb has a potential upside of 15.9% from its current price of $55.53.
Amount of Analyst Coverage
Bristol-Myers Squibb has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.6 Community Rank

Outperform Votes
Bristol-Myers Squibb has received 1,006 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Bristol-Myers Squibb has received 912 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Bristol-Myers Squibb has received 52.45% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Bristol-Myers Squibb and other stocks. Vote “Outperform” if you believe BMY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BMY will underperform the S&P 500 over the long term. You may vote once every thirty days.

5.0 Dividend Strength

Dividend Leadership
Bristol-Myers Squibb is a leading dividend payer. It pays a dividend yield of 3.26%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Bristol-Myers Squibb has been increasing its dividend for 10 years.
Dividend Coverage
The dividend payout ratio of Bristol-Myers Squibb is 38.38 %. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Bristol-Myers Squibb will have a dividend payout ratio of 24.52 % next year. This indicates that Bristol-Myers Squibb will be able to sustain or increase its dividend.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bristol-Myers Squibb insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $964,263.00 in company stock.
Percentage Held by Insiders
Only 0.13% of the stock of Bristol-Myers Squibb is held by insiders.
Percentage Held by Institutions
77.88% of the stock of Bristol-Myers Squibb is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Bristol-Myers Squibb are expected to grow by 19.35% in the coming year, from $6.15 to $7.34 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Bristol-Myers Squibb is 25.36, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 10.36.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bristol-Myers Squibb is 25.36, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 14.97.
Price to Earnings Growth Ratio
Bristol-Myers Squibb has a PEG Ratio of 1.22. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Bristol-Myers Squibb has a P/B Ratio of 2.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.53 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

Current SymbolNYSE:BMY

Previous Symbol

CUSIP11012210

CIK14272

Webhttp://www.bms.com/

Phone212-546-4000

Debt

Debt-to-Equity Ratio0.84

Current Ratio1.60

Quick Ratio1.37

Price-To-Earnings

Trailing P/E Ratio25.36

Forward P/E Ratio9.03

P/E Growth1.22

Sales & Book Value

Annual Sales$26.15 billion

Price / Sales4.79

Cash Flow$4.41 per share

Price / Cash Flow12.58

Book Value$23.20 per share

Price / Book2.39

Profitability

EPS (Most Recent Fiscal Year)$4.69

Net Income$3.44 billion

Net Margins13.15%

Return on Equity31.85%

Return on Assets11.59%

Miscellaneous

Employees30,000

Outstanding Shares2,257,510,000

Market Cap$125.36 billion

Next Earnings Date5/7/2020 (Confirmed)

OptionableOptionable

Receive BMY News and Ratings via Email

Sign-up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.

Bristol-Myers Squibb (NYSE:BMY) Frequently Asked Questions

How has Bristol-Myers Squibb's stock been impacted by COVID-19 (Coronavirus)?

Bristol-Myers Squibb's stock was trading at $56.51 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BMY shares have decreased by 1.7% and is now trading at $55.53. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Bristol-Myers Squibb?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last year. There are currently 3 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Bristol-Myers Squibb.

When is Bristol-Myers Squibb's next earnings date?

Bristol-Myers Squibb is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Bristol-Myers Squibb.

How can I listen to Bristol-Myers Squibb's earnings call?

Bristol-Myers Squibb will be holding an earnings conference call on Thursday, May 7th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Bristol-Myers Squibb's earnings last quarter?

Bristol-Myers Squibb Co (NYSE:BMY) announced its earnings results on Thursday, February, 6th. The biopharmaceutical company reported $1.22 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.88 by $0.34. The biopharmaceutical company earned $7.95 billion during the quarter, compared to analyst estimates of $6.20 billion. Bristol-Myers Squibb had a return on equity of 31.85% and a net margin of 13.15%. Bristol-Myers Squibb's revenue for the quarter was up 33.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.94 EPS. View Bristol-Myers Squibb's earnings history.

How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb?

Bristol-Myers Squibb announced a quarterly dividend on Monday, March 2nd. Shareholders of record on Friday, April 3rd will be given a dividend of $0.45 per share on Friday, May 1st. This represents a $1.80 annualized dividend and a dividend yield of 3.24%. The ex-dividend date of this dividend is Thursday, April 2nd. View Bristol-Myers Squibb's dividend history.

What guidance has Bristol-Myers Squibb issued on next quarter's earnings?

Bristol-Myers Squibb updated its FY20 earnings guidance on Thursday, February, 6th. The company provided earnings per share guidance of $6.00-$6.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.20. The company issued revenue guidance of $40.5-$42.50 billion, compared to the consensus revenue estimate of $42.21 billion.

What price target have analysts set for BMY?

15 analysts have issued twelve-month target prices for Bristol-Myers Squibb's stock. Their forecasts range from $50.00 to $80.00. On average, they expect Bristol-Myers Squibb's stock price to reach $64.33 in the next twelve months. This suggests a possible upside of 15.9% from the stock's current price. View analysts' price targets for Bristol-Myers Squibb.

Has Bristol-Myers Squibb been receiving favorable news coverage?

News headlines about BMY stock have trended very negative recently, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Bristol-Myers Squibb earned a news impact score of -3.3 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutBristol-Myers Squibb.

Who are some of Bristol-Myers Squibb's key competitors?

Some companies that are related to Bristol-Myers Squibb include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Horizon Therapeutics (HZNP), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Corcept Therapeutics (CORT), Pacira Biosciences (PCRX) and Zogenix (ZGNX).

What other stocks do shareholders of Bristol-Myers Squibb own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bristol-Myers Squibb investors own include AbbVie (ABBV), AT&T (T), Pfizer (PFE), Chicago Bridge & Iron (CBI), Bank of America (BAC), Verizon Communications (VZ), Intel (INTC), CVS Health (CVS), Walt Disney (DIS) and Diebold Nixdorf (DBD).

Who are Bristol-Myers Squibb's key executives?

Bristol-Myers Squibb's management team includes the following people:

Dr. Giovanni Caforio, Chairman & CEO (Age 54)
Mr. Charles A. Bancroft, Exec. VP of Global Bus. Operations & CFO (Age 59)
Dr. Thomas J. Lynch Jr., Exec. VP & Chief Scientific Officer (Age 58)
Ms. Sandra Leung Esq., Exec. VP & Gen. Counsel (Age 58)
Mr. Paul von Autenried, Sr. VP & Chief Information Officer (Age 57)

What is Bristol-Myers Squibb's stock symbol?

Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

Who are Bristol-Myers Squibb's major shareholders?

Bristol-Myers Squibb's stock is owned by many different institutional and retail investors. Top institutional shareholders include Cullinan Associates Inc. (0.01%), Neville Rodie & Shaw Inc. (0.01%), Private Asset Management Inc. (0.01%), Cacti Asset Management LLC (0.00%), Fulton Bank N.A. (0.00%) and Blackhawk Capital Partners LLC. (0.00%). Company insiders that own Bristol-Myers Squibb stock include Dinesh C Paliwal, John E Elicker, Karen Murphy Santiago, Louis S Schmukler, Robert J Bertolini and Theodore R Samuels II. View institutional ownership trends for Bristol-Myers Squibb.

Which major investors are selling Bristol-Myers Squibb stock?

BMY stock was sold by a variety of institutional investors in the last quarter, including Neville Rodie & Shaw Inc., Thomasville National Bank, Cacti Asset Management LLC, Cullinan Associates Inc., M&R Capital Management Inc., First Financial Bank Trust Division, Blackhawk Capital Partners LLC., and Salomon & Ludwin LLC. Company insiders that have sold Bristol-Myers Squibb company stock in the last year include John E Elicker, Karen Murphy Santiago, and Louis S Schmukler. View insider buying and selling activity for Bristol-Myers Squibb.

Which major investors are buying Bristol-Myers Squibb stock?

BMY stock was purchased by a variety of institutional investors in the last quarter, including Private Asset Management Inc., IMS Capital Management, and Fulton Bank N.A.. Company insiders that have bought Bristol-Myers Squibb stock in the last two years include Dinesh C Paliwal, Robert J Bertolini, and Theodore R Samuels II. View insider buying and selling activity for Bristol-Myers Squibb.

How do I buy shares of Bristol-Myers Squibb?

Shares of BMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Bristol-Myers Squibb's stock price today?

One share of BMY stock can currently be purchased for approximately $55.53.

How big of a company is Bristol-Myers Squibb?

Bristol-Myers Squibb has a market capitalization of $125.36 billion and generates $26.15 billion in revenue each year. The biopharmaceutical company earns $3.44 billion in net income (profit) each year or $4.69 on an earnings per share basis. Bristol-Myers Squibb employs 30,000 workers across the globe. View additional information about Bristol-Myers Squibb.

What is Bristol-Myers Squibb's official website?

The official website for Bristol-Myers Squibb is http://www.bms.com/.

How can I contact Bristol-Myers Squibb?

Bristol-Myers Squibb's mailing address is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 212-546-4000 or via email at [email protected]

This page was last updated on 4/4/2020 by MarketBeat.com Staff

Featured Article: Moving Average - How it Helps Investors in Stock Selection

NYSE:BMYBristol-Myers Squibb Stock Price, Forecast & News

Adding

Adding

Adding Bristol-Myers Squibb Co

Beat the Market (BTM) Rank™

3.4 Analyst's Opinion

Consensus Rating

Price Target Upside/Downside

Amount of Analyst Coverage

2.6 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment